DK1697371T3 - Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer - Google Patents

Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer

Info

Publication number: DK1697371T3
Authority: DK; Denmark
Prior art keywords: azabicyclic; heterocyclic compounds; receptor modulators; cannabinoid receptor; formula
Prior art date: 2003-12-19

Application number

DK04815007T

Other languages

Danish (da)

English (en)

Inventor

Guixue Gu

William R Ewing

Amarendra B Mikkilineni

Annapurna Pendri

Bruce A Ellsworth

Philip M Sher

Samuel Gerritz

Chongqing Sun

Natesan Murugesan

Ximao Wu

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-19

Filing date

2004-12-17

Publication date

2007-09-17

2004-12-17 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2007-09-17 Application granted granted Critical

2007-09-17 Publication of DK1697371T3 publication Critical patent/DK1697371T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)
Addiction (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)

DK04815007T 2003-12-19 2004-12-17 Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer DK1697371T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US53145103P	2003-12-19	2003-12-19
PCT/US2004/042878 WO2005063762A1 (en)	2003-12-19	2004-12-17	Azabicyclic heterocycles as cannabinoid receptor modulators
US11/016,198 US7816357B2 (en)	2003-12-19	2004-12-17	Azabicyclic heterocycles as cannabinoid receptor modulators

Publications (1)

Publication Number	Publication Date
DK1697371T3 true DK1697371T3 (da)	2007-09-17

Family

ID=34742367

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04815007T DK1697371T3 (da)	2003-12-19	2004-12-17	Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer

Country Status (20)

Country	Link
US (1)	US7816357B2 (pl)
EP (1)	EP1697371B1 (pl)
JP (1)	JP2007514770A (pl)
KR (1)	KR20060103265A (pl)
AT (1)	ATE360631T1 (pl)
AU (1)	AU2004309368A1 (pl)
BR (1)	BRPI0417820A (pl)
CA (1)	CA2550375A1 (pl)
CY (1)	CY1106679T1 (pl)
DE (1)	DE602004006166T2 (pl)
DK (1)	DK1697371T3 (pl)
ES (1)	ES2284081T3 (pl)
HR (1)	HRP20070267T3 (pl)
IL (1)	IL176110A0 (pl)
IS (1)	IS8503A (pl)
NO (1)	NO20062691L (pl)
PL (1)	PL1697371T3 (pl)
PT (1)	PT1697371E (pl)
RU (1)	RU2006126123A (pl)
WO (1)	WO2005063762A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1697371E (pt)	2003-12-19	2007-08-03	Bristol Myers Squibb Co	Heterocíclos azabicíclicos como moduladores do receptor de canabinóides
WO2006039334A1 (en) *	2004-09-29	2006-04-13	Schering Corporation	Combinations of substituted azetidonones and cb1 antagonists
ES2325773T5 (es) *	2004-11-01	2014-02-24	Amylin Pharmaceuticals, Llc.	Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en)	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
US7452892B2 (en)	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en)	2005-06-17	2009-12-08	Bristol-Myers Squibb Company	Azabicyclic heterocycles as cannabinoid receptor modulators
WO2007055743A2 (en) *	2005-11-01	2007-05-18	Amylin Pharmaceuticals, Inc.	Treatment of obesity and related disorders
BRPI0619516B1 (pt)	2005-12-07	2015-09-15	Sumitomo Chemical Co	composto de piridazina e uso do mesmo, bem como agente e método de controle de doença de planta
DK1958948T3 (da)	2005-12-07	2011-10-31	Sumitomo Chemical Co	Pyridazinforbindelse og anvendelse deraf
EP1988883A1 (fr) *	2006-02-17	2008-11-12	Trimaran Limited	Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US20080027087A1 (en) *	2006-02-21	2008-01-31	Ampla Pharmaceuticals, Inc.	CB1 antagonists and inverse agonists
WO2008021666A2 (en) *	2006-08-18	2008-02-21	Morton Grove Pharmaceuticals, Inc.	Stable liquid levetiracetam compositions and methods
US20080140450A1 (en) *	2006-11-28	2008-06-12	Ampla Pharmaceuticals Inc.	Treatment of metabolic syndrome with norfluoxetine
ATE554092T1 (de)	2006-12-14	2012-05-15	Bristol Myers Squibb Co	Azabicyclische heterocyclen als cannabinoid- rezeptormodulatoren
FR2910001B1 (fr) *	2006-12-18	2009-03-20	Sod Conseils Rech Applic	Derives d'imidazo, pyrimido et diazepine pyrimidine-dione et leur utilisation comme medicament
AR064962A1 (es) *	2007-01-22	2009-05-06	Syngenta Participations Ag	Derivados de piridazina utiles como fungicidas
JP2008222603A (ja) *	2007-03-09	2008-09-25	Institute Of Physical & Chemical Research	神経変性疾患の予防・治療剤
US11241420B2 (en)	2007-04-11	2022-02-08	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
DE102008000872A1 (de)	2007-04-11	2008-11-13	Basf Se	Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel
ES2830073T3 (es)	2007-04-11	2021-06-02	Omeros Corp	Composiciones y métodos para la profilaxis y el tratamiento de adicciones
US20160331729A9 (en)	2007-04-11	2016-11-17	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
JP5485148B2 (ja) *	2007-06-21	2014-05-07	カラセラピューティクスインコーポレイテッド	置換イミダゾ複素環
US20090036426A1 (en) *	2007-07-30	2009-02-05	Ampla Pharmaceuticals Inc.	CB1 antagonists and inverse agonists
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0722276A2 (pt) *	2007-11-14	2014-04-22	Amylin Pharmaceuticals Inc	Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
WO2010079241A1 (es) *	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
JP2013538215A (ja)	2010-08-31	2013-10-10	エスエヌユーアールアンドディービーファウンデーション	ＰＰＡＲδアゴニストの胎児再プログラミング用途
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012142388A2 (en) *	2011-04-15	2012-10-18	New York University	Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
JP5437525B1 (ja)	2012-12-28	2014-03-12	株式会社ナード研究所	チロシン誘導体およびチロシン誘導体の製造方法
WO2014154606A1 (en)	2013-03-27	2014-10-02	F. Hoffmann-La Roche Ag	Genetic markers for predicting responsiveness to therapy
PE20161393A1 (es) *	2014-01-29	2017-01-08	Neuropore Therapies Inc	Heteroaril amidas como inhibidores de agregacion de proteina
WO2016016157A1 (en)	2014-07-30	2016-02-04	F. Hoffmann-La Roche Ag	Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
US20210393621A1 (en)	2018-10-26	2021-12-23	The Research Foundation For The State University Of New York	Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR102503349B1 (ko)	2019-05-14	2023-02-23	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
US12006366B2 (en)	2020-06-11	2024-06-11	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3994898A (en) *	1975-10-16	1976-11-30	E. R. Squibb & Sons, Inc.	1,2,4-Triazolo (4,3-b) pyridazin-3-ones
IT1164198B (it)	1983-04-28	1987-04-08	Isf Spa	Preparazione di un derivato piridazinico farmacologicamente attivo
JPS61106576A (ja)	1984-10-31	1986-05-24	Nippon Soda Co Ltd	トリアゾロピリダジン−３−オン誘導体及び製造方法
EP0915875B1 (en)	1996-07-25	2003-04-09	MERCK SHARP & DOHME LTD.	Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
AU6003099A (en)	1998-10-06	2000-04-26	Takeda Chemical Industries Ltd.	Fused pyridazine compounds, process for the preparation of the same and uses thereof
US6653304B2 (en)	2000-02-11	2003-11-25	Bristol-Myers Squibb Co.	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
JP2002205992A (ja)	2000-11-08	2002-07-23	Takeda Chem Ind Ltd	二環式トリアゾロン誘導体およびそれを含有する除草剤
GB0107751D0 (en) *	2001-03-28	2001-05-16	Pfizer Ltd	Pharmaceutically active compounds
AU2002319627A1 (en)	2001-07-20	2003-03-03	Merck And Co., Inc.	Substituted imidazoles as cannabinoid receptor modulators
MXPA04007713A (es) *	2002-02-07	2004-11-10	Pfizer	Uso de inhibidores de la fosfodiesterasa tipo 5, tal como sildenafil, en el tratamiento del sindrome de ovario poliquistico.
ATE373660T1 (de) *	2002-03-25	2007-10-15	Merck & Co Inc	Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
EP1594848A1 (en)	2003-02-19	2005-11-16	Neurogen Corporation	Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds
PT1697371E (pt)	2003-12-19	2007-08-03	Bristol Myers Squibb Co	Heterocíclos azabicíclicos como moduladores do receptor de canabinóides
TW200528455A (en)	2003-12-19	2005-09-01	Bristol Myers Squibb Co	Azabicyclic heterocycles as cannabinoid receptor modulators

2004
- 2004-12-17 PT PT04815007T patent/PT1697371E/pt unknown
- 2004-12-17 CA CA002550375A patent/CA2550375A1/en not_active Abandoned
- 2004-12-17 US US11/016,198 patent/US7816357B2/en active Active
- 2004-12-17 WO PCT/US2004/042878 patent/WO2005063762A1/en not_active Ceased
- 2004-12-17 PL PL04815007T patent/PL1697371T3/pl unknown
- 2004-12-17 BR BRPI0417820-3A patent/BRPI0417820A/pt not_active IP Right Cessation
- 2004-12-17 KR KR1020067011999A patent/KR20060103265A/ko not_active Withdrawn
- 2004-12-17 JP JP2006545567A patent/JP2007514770A/ja active Pending
- 2004-12-17 RU RU2006126123/04A patent/RU2006126123A/ru not_active Application Discontinuation
- 2004-12-17 EP EP04815007A patent/EP1697371B1/en not_active Expired - Lifetime
- 2004-12-17 HR HR20070267T patent/HRP20070267T3/xx unknown
- 2004-12-17 ES ES04815007T patent/ES2284081T3/es not_active Expired - Lifetime
- 2004-12-17 DE DE602004006166T patent/DE602004006166T2/de not_active Expired - Fee Related
- 2004-12-17 AT AT04815007T patent/ATE360631T1/de not_active IP Right Cessation
- 2004-12-17 AU AU2004309368A patent/AU2004309368A1/en not_active Abandoned
- 2004-12-17 DK DK04815007T patent/DK1697371T3/da active
2006
- 2006-06-04 IL IL176110A patent/IL176110A0/en unknown
- 2006-06-08 IS IS8503A patent/IS8503A/xx unknown
- 2006-06-12 NO NO20062691A patent/NO20062691L/no not_active Application Discontinuation
2007
- 2007-06-26 CY CY20071100845T patent/CY1106679T1/el unknown

Also Published As

Publication number	Publication date
PL1697371T3 (pl)	2007-09-28
DE602004006166D1 (de)	2007-06-06
HRP20070267T3 (hr)	2007-08-31
US7816357B2 (en)	2010-10-19
BRPI0417820A (pt)	2007-03-27
EP1697371B1 (en)	2007-04-25
HK1095138A1 (en)	2007-04-27
DE602004006166T2 (de)	2008-01-10
KR20060103265A (ko)	2006-09-28
CY1106679T1 (el)	2012-05-23
US20050171110A1 (en)	2005-08-04
ATE360631T1 (de)	2007-05-15
ES2284081T3 (es)	2007-11-01
JP2007514770A (ja)	2007-06-07
CA2550375A1 (en)	2005-07-14
EP1697371A1 (en)	2006-09-06
AU2004309368A1 (en)	2005-07-14
IL176110A0 (en)	2006-10-05
PT1697371E (pt)	2007-08-03
NO20062691L (no)	2006-09-14
IS8503A (is)	2006-06-08
RU2006126123A (ru)	2008-01-27
WO2005063762A1 (en)	2005-07-14

Publication	Publication Date	Title
DK1697371T3 (da)	2007-09-17	Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
DK1697370T3 (da)	2007-09-17	Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
TW200726765A (en)	2007-07-16	Triazolopyridine cannabinoid receptor 1 antagonists
NO20062689L (no)	2006-09-12	Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20076357L (no)	2008-03-14	Azabicykliske heterocykler som cannabinoid reseptor modulatorer
WO2005037199A3 (en)	2005-08-04	Pyrazole derivatives as cannabinoid receptor modulators
SE0401342D0 (sv)	2004-05-25	Therapeutic compounds
EA200500018A1 (ru)	2005-06-30	Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
SE0401345D0 (sv)	2004-05-25	Therapeutic compounds: Pyridine as scaffold
WO2006044362A3 (en)	2006-12-07	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
SE0402762D0 (sv)	2004-11-11	Indazole sulphonamide derivatives
MY140630A (en)	2010-01-15	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UY27685A1 (es)	2003-10-31	Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
SE0301701D0 (sv)	2003-06-10	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301320D0 (sv)	2003-05-06	Positive modulators of nicotinic acetylcholine receptors
SE0301699D0 (sv)	2003-06-10	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv)	2003-09-26	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE602005010744D1 (de)	2008-12-11	Piperazinylpyridinderivate als mittel gegen adipositas
TW200626581A (en)	2006-08-01	Compounds, compositions containing them, preparation thereof and uses thereof
NO20092230L (no)	2009-07-13	Azabicykliske heterocykler som cannabinoid reseptor modulatorer
WO2006076598A3 (en)	2006-08-24	Bicyclic heterocycles as cannabinoid receptor modulators
ATE465151T1 (de)	2010-05-15	4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
WO2006076569A3 (en)	2006-12-21	Bicyclic heterocycles as cannabinoid receptor modulators
SE0402763D0 (sv)	2004-11-11	Nitro indazole derivatives
PL1732902T3 (pl)	2010-06-30	Pochodne nukleozydów i ich terapeutyczne zastosowanie